modafinil has been researched along with Chronic Insomnia in 23 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 9.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors." | 9.22 | Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 9.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "We conducted a multisite, double-blind, placebo-controlled study of the treatment of major depression characterized by excessive sleepiness and fatigue, adding adjunctive modafinil or placebo to a selective serotonin reuptake inhibitor from the beginning of treatment." | 9.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| "To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)." | 9.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "The primary outcome measure was the insomnia severity index (ISI), and secondary outcomes were the Epworth sleepiness scale, sleep restriction adherence scale (SRAS), and safety from baseline through to 12 weeks." | 7.30 | Armodafinil to reduce the sleepiness related side-effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls. ( Bartlett, DJ; Espie, CA; Grunstein, RR; Jomaa, I; Judge, DJ; Kyle, SD; Marshall, NS; Miller, CB; Saini, B; Semsarian, CR; Wong, KKW; Yee, BJ, 2023) |
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 5.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors." | 5.22 | Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016) |
| "Patients with ES associated with treated OSA, SWD, or narcolepsy who completed one of four 12-week, double-blind studies were eligible for this multicenter, open-label study of > or = 12 months' duration of treatment with armodafinil (50 to 250 mg/day)." | 5.14 | The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. ( Black, JE; Harsh, JR; Hull, SG; Tiller, J; Yang, R, 2010) |
| "We conducted a multisite, double-blind, placebo-controlled study of the treatment of major depression characterized by excessive sleepiness and fatigue, adding adjunctive modafinil or placebo to a selective serotonin reuptake inhibitor from the beginning of treatment." | 5.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
| "To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)." | 5.11 | Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. ( Clanet, M; Confavreux, C; Debouverie, M; Edan, G; Lubetzki, C; Moreau, T; Pelletier, J; Rumbach, L; Stankoff, B; Waubant, E, 2005) |
| "The primary outcome measure was the insomnia severity index (ISI), and secondary outcomes were the Epworth sleepiness scale, sleep restriction adherence scale (SRAS), and safety from baseline through to 12 weeks." | 3.30 | Armodafinil to reduce the sleepiness related side-effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls. ( Bartlett, DJ; Espie, CA; Grunstein, RR; Jomaa, I; Judge, DJ; Kyle, SD; Marshall, NS; Miller, CB; Saini, B; Semsarian, CR; Wong, KKW; Yee, BJ, 2023) |
| "This phenomenon has been termed "occult insomnia." | 2.84 | Sleep Perception and Misperception in Chronic Cocaine Users During Abstinence. ( Hodges, SE; Morgan, PT; Pittman, B, 2017) |
| "Cancer-related insomnia is associated with diminished quality of life (QOL), suggesting that improvement in insomnia may improve QOL in cancer survivors." | 2.84 | Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Peoples, AR; Peppone, LJ; Perlis, ML; Roscoe, JA; Ryan, JL; Savard, J, 2017) |
| " Headache, insomnia, and anxiety were the most common adverse events (AEs) reported, whereas akathisia, nausea, sedation/somnolence, and weight increase were uncommon." | 2.82 | Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study. ( Amchin, J; Frye, MA; Gross, N; Ketter, TA, 2016) |
| "We report on a randomized trial of 96 cancer survivors (mean age, 56 years; female, 87." | 2.80 | Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. ( Daniels, NP; Garland, SN; Heckler, CE; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Savard, J; Shayne, M, 2015) |
| "Past zolpidem use was reported by 21." | 2.74 | Modafinil and zolpidem use by emergency medicine residents. ( Ankel, FK; Asplin, BR; Flottemesch, TJ; Ling, LJ; Mason, EJ; McBeth, BD; McNamara, RM, 2009) |
| "30 subjects with primary insomnia were enrolled in this study and were randomly assigned to 1 of 3 treatment conditions: (1) placebo plus CBT, (2) 100 mg modafinil plus CBT, or (3) 100 mg modafinil plus a contact control (monitor-only condition)." | 2.71 | The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. ( Enright, T; Jungquist, C; Nowakowski, S; Orff, H; Perlis, ML; Plotkin, K; Smith, MT, 2004) |
| " Serial blood samples were obtained following administration of the day 1 and day 7 doses for characterization of pharmacokinetics, and trough samples were obtained prior to dosing on days 2 through 6 to assess the time to reach the steady state." | 2.69 | A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. ( Grebow, PE; Hartman, LN; King, SP; Laughton, WB; McCormick, GC; Simcoe, D; Wong, YN, 1999) |
| "Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine." | 2.66 | Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. ( Dinis-Oliveira, RJ; Sousa, A, 2020) |
| " Approaches to the management of residual symptoms include addressing treatment-emergent side effects and co-morbid conditions, optimizing antidepressant dosing and using augmentation therapy." | 2.43 | Pharmacological approaches to the treatment of residual symptoms. ( Fava, M, 2006) |
| "Whether insomnia is a precursor, symptom, residual symptom, or side effect of depression or its treatment, clinicians must give serious attention to and attempt to resolve sleep disturbances because of the risk of depression onset, worsening of depressive symptoms, and relapse of depression after response to antidepressant treatment." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Judge, DJ | 1 |
| Miller, CB | 1 |
| Bartlett, DJ | 1 |
| Jomaa, I | 1 |
| Wong, KKW | 1 |
| Saini, B | 1 |
| Semsarian, CR | 1 |
| Espie, CA | 1 |
| Kyle, SD | 1 |
| Grunstein, RR | 1 |
| Yee, BJ | 1 |
| Marshall, NS | 1 |
| Sousa, A | 1 |
| Dinis-Oliveira, RJ | 1 |
| Hodges, SE | 1 |
| Pittman, B | 1 |
| Morgan, PT | 1 |
| Ooi, T | 1 |
| Wong, SH | 1 |
| See, B | 1 |
| Roscoe, JA | 4 |
| Garland, SN | 4 |
| Heckler, CE | 4 |
| Perlis, ML | 5 |
| Peoples, AR | 4 |
| Shayne, M | 2 |
| Savard, J | 2 |
| Daniels, NP | 1 |
| Morrow, GR | 4 |
| Lecendreux, M | 1 |
| Lavault, S | 1 |
| Lopez, R | 1 |
| Inocente, CO | 1 |
| Konofal, E | 1 |
| Cortese, S | 1 |
| Franco, P | 1 |
| Arnulf, I | 1 |
| Dauvilliers, Y | 1 |
| Kamen, C | 2 |
| Hoefler, J | 1 |
| Ketter, TA | 1 |
| Amchin, J | 1 |
| Frye, MA | 1 |
| Gross, N | 1 |
| Barilla, H | 1 |
| Gehrman, P | 1 |
| Findley, JC | 1 |
| Kamen, CS | 1 |
| Ryan, JL | 1 |
| Mustian, KM | 1 |
| Janelsins, MC | 1 |
| Peppone, LJ | 1 |
| McBeth, BD | 1 |
| McNamara, RM | 1 |
| Ankel, FK | 1 |
| Mason, EJ | 1 |
| Ling, LJ | 1 |
| Flottemesch, TJ | 1 |
| Asplin, BR | 1 |
| Thorpy, MJ | 1 |
| Black, JE | 1 |
| Hull, SG | 1 |
| Tiller, J | 1 |
| Yang, R | 1 |
| Harsh, JR | 1 |
| Smith, MT | 1 |
| Orff, H | 1 |
| Enright, T | 1 |
| Nowakowski, S | 1 |
| Jungquist, C | 1 |
| Plotkin, K | 1 |
| Fava, M | 2 |
| Stankoff, B | 1 |
| Waubant, E | 1 |
| Confavreux, C | 1 |
| Edan, G | 1 |
| Debouverie, M | 1 |
| Rumbach, L | 1 |
| Moreau, T | 1 |
| Pelletier, J | 1 |
| Lubetzki, C | 1 |
| Clanet, M | 1 |
| Howcroft, DJ | 1 |
| Jones, RW | 1 |
| Basner, RC | 1 |
| Bonnet, MH | 1 |
| Balkin, TJ | 1 |
| Dinges, DF | 1 |
| Roehrs, T | 1 |
| Rogers, NL | 1 |
| Wesensten, NJ | 1 |
| Dunlop, BW | 1 |
| Crits-Christoph, P | 1 |
| Evans, DL | 1 |
| Hirschowitz, J | 1 |
| Solvason, HB | 1 |
| Rickels, K | 1 |
| Garlow, SJ | 1 |
| Gallop, RJ | 1 |
| Ninan, PT | 1 |
| Wong, YN | 1 |
| Simcoe, D | 1 |
| Hartman, LN | 1 |
| Laughton, WB | 1 |
| King, SP | 1 |
| McCormick, GC | 1 |
| Grebow, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy[NCT01091974] | Phase 2 | 138 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase 4 Study of the Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia[NCT00124384] | Phase 4 | 40 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| Is Insomnia a Modifiable Risk Factor for Major Depressive Disorder[NCT00255905] | 45 participants (Anticipated) | Interventional | 2004-07-31 | Completed | |||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Comparison Between the Effects on Fatigue of Aerobic Training Versus Balance Training in Patients With Multiple Sclerosis: a Randomised Crossover Trial.[NCT06051019] | 39 participants (Actual) | Interventional | 2016-02-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia. (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | -4.93 |
| 2 - CBT-I + Armodafinil | -6.36 |
| 3- Placebo Only | 1.04 |
| 4 - Armodafinil Only | -1.43 |
"The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue now, and fatigue at its worst and usual for the last 24 hours. The 11-point scales are bounded by 0 = no fatigue and 10 = fatigue as bad as you can imagine. Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = does not interfere and 10 = interferes completely. A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI." (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | 2.041 |
| 2 - CBT-I + Armodafinil | 1.209 |
| 3- Placebo Only | 2.971 |
| 4 - Armodafinil Only | 3.167 |
5 reviews available for modafinil and Chronic Insomnia
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.
Topics: Anxiety; Diarrhea; Drug Eruptions; Drug Interactions; Erythema Multiforme; Forensic Sciences; Headac | 2020 |
Managing the patient with shift-work disorder.
Topics: Benzhydryl Compounds; Combined Modality Therapy; Diet; Environment; Exercise; Female; Humans; Life S | 2010 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and Stimulant Task Force of the American Academy of Sleep Medicine.
Topics: Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Humans; Methamphetamine; Modafini | 2005 |
Pharmacological approaches to the treatment of residual symptoms.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Benzhydryl Compounds; Benzodiazepines; Central | 2006 |
14 trials available for modafinil and Chronic Insomnia
| Article | Year |
|---|---|
Armodafinil to reduce the sleepiness related side-effects of sleep restriction therapy being used to treat insomnia disorder: An open label clinical trial pilot study compared with historical controls.
Topics: Humans; Modafinil; Pilot Projects; Sleep Initiation and Maintenance Disorders; Sleepiness; Treatment | 2023 |
Sleep Perception and Misperception in Chronic Cocaine Users During Abstinence.
Topics: Adult; Benzhydryl Compounds; Cocaine-Related Disorders; Double-Blind Method; Female; Humans; Male; M | 2017 |
Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cognitive Behavioral Therapy; Combined Modality Therapy; Fem | 2015 |
Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial.
Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; Female; Foll | 2016 |
Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study.
Topics: Adult; Aged; Anxiety; Benzhydryl Compounds; Bipolar Disorder; Double-Blind Method; Female; Headache; | 2016 |
Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors.
Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Disorders of Excessive Somnolence; Female; Human | 2016 |
Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; | 2017 |
Modafinil and zolpidem use by emergency medicine residents.
Topics: Adult; Akathisia, Drug-Induced; Amnesia; Anorexia; Benzhydryl Compounds; Central Nervous System Stim | 2009 |
The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Central Nervous System Stimulants; Double-Blind Method; | 2010 |
The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognitive Behavioral Therapy; Female; Humans; Male; Middle A | 2004 |
The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognitive Behavioral Therapy; Female; Humans; Male; Middle A | 2004 |
The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognitive Behavioral Therapy; Female; Humans; Male; Middle A | 2004 |
The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia.
Topics: Adult; Benzhydryl Compounds; Cognition; Cognitive Behavioral Therapy; Female; Humans; Male; Middle A | 2004 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female | 2005 |
Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia?
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous System Stimulants; Circadian Rhythm; | 2005 |
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2007 |
A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.
Topics: Adolescent; Adult; Anxiety; Area Under Curve; Benzhydryl Compounds; Central Nervous System Stimulant | 1999 |
4 other studies available for modafinil and Chronic Insomnia
| Article | Year |
|---|---|
Modafinil as a Stimulant for Military Aviators.
Topics: Accidents, Aviation; Adult; Aerospace Medicine; Anxiety; Central Nervous System Stimulants; Diarrhea | 2019 |
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Control Studie | 2015 |
Sleepiness versus sleeplessness: shift work and sleep disorders.
Topics: Amphetamines; Benzhydryl Compounds; Central Nervous System Stimulants; Circadian Rhythm; Diagnosis, | 2004 |
Shift-work sleep disorder--the glass is more than half empty.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Humans; | 2005 |